RC48

disitamab vedotin · RemeGen

Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for RC48, covering 2021-11-26 to 2025-09-26. Get the full timeline:

Most recent: Clinical Trial Update: Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer [Phase 2]